Objective:

To investigate the feasibility

safety and therapeutic value of ultrasound-guided percutaneous laser ablation for primary hyperparathyroidism (PHPT).

Methods:

Three patients with PHPT were treated with laser ablation. The multi-point ablation power was 3W

and the contrast-enhanced ultrasound was used to evaluate the ablation range immediately after surgery. The changes o

f intact parathyroid hormone (iPTH)

serum calcium

serum phosphorus

alkaline phosphatase (ALP) and parathyroid nodule volume were measured before and after operation for 12 months.

Results:

A total of 3 cases of PHPT nodules were completely ablated at one time

confirmed by contrast-enhanced ultrasound. 12 months after operation

iPTH decreased from (578.37 568.66) ng/L to (92.6219.83) ng/L

serum calcium decreased from (3.200.43) mmol/L to (2.350.03) mmol/L (

P

＜0.05)

and ALP decreased from (303.53188.29) U/L to (99.707.86) U/L. Serum phosphorus rose from (0.8300.098) mmol/L to (0.9230.120) mmol/L. Postoperative iPTH decreased significantly. The blood calcium

blood phosphorus and ALP continued to be normal levels. The nodule volume reduction rate was ＞95.73%. One case of postoperative bone starvation syndrome was treated with oral calcium supplementation

and no serious complications such as recurrent laryngeal nerve injury occurred.

Conclusion:

Ultrasound-guided percutaneous laser ablation of PHPT is a minimally invasive

safe and effective method

which can significantly reduce iPTH

serum calcium measurements and significantly reduce the volume of parathyroid nodules. It can be a new method for the treatment of PHPT.